Highest-materiality recent filing
On Aug 18, 2026, UroGen U.S. entered an Option and Research License Agreement with IntraGel Therapeutics for TumoCure (head and neck cancer).
UroGen Q2 2026: ZUSDURI revenue $50.4M (+73% QoQ); net loss narrows to $14.4M
Total revenue $72.5M (Q2 2026) vs $24.2M (Q2 2025), driven by ZUSDURI launch.
UroGen settles patent litigation with Teva over Jelmyto; generic entry Sept 15, 2030
Settlement resolves patent litigation regarding Teva's generic version of Jelmyto (mitomycin) for pyelocalyceal solution.
UroGen Q1 2026: ZUSDURI revenue $29.2M (+109% QoQ); net loss narrows to $0.47/share
Total revenue $51.0M, up 152% YoY on ZUSDURI launch and JELMYTO growth.
UroGen Pharma secures up to $250M loan at 8.25%; $200M funded to refinance existing debt
Tranche A of $200M funded on Feb 26, used to refinance $125M existing term loan and fund working capital.
UroGen reports FY2025 net loss $153.5M; ZUSDURI launch net sales $15.8M; refinances debt at 8.25%
FY2025 revenue $109.8M (+21% YoY); JELMYTO net sales $94M (underlying demand +7%).
UroGen Q3: ZUSDURI rev $1.8M, Oct estimate $4.5M; JELMYTO +13% YoY; net loss $33.3M
ZUSDURI achieved net product revenue of $1.8M in Q3; October 2025 preliminary demand revenue estimate of $4.5M, with 592 activated sites and 54 prescribers since July launch.
UroGen reports Q2 loss of $49.9M; launches ZUSDURI after June FDA approval
ZUSDURI (mitomycin) FDA-approved June 12 for recurrent LG-IR-NMIBC; now commercially available.
UroGen awards special bonuses totaling $845K to CEO, CFO, GC for ZUSDURI FDA approval
CEO Elizabeth Barrett receives $645,000; CFO Chris Degnan and GC Jason Smith each get $100,000.
FDA approves UroGen Pharma's ZUSDURI (mitomycin) for recurrent LG-IR-NMIBC
FDA approved ZUSDURI (mitomycin) for adults with recurrent low-grade intermediate-risk NMIBC on June 12, 2025.
UroGen Pharma Q1 2025: JELMYTO revenue $20.3M, net loss widens to $43.8M; UGN-102 PDUFA June 13
JELMYTO net sales $20.3M (+8% YoY); underlying demand grew 12%.
UroGen reports Q4/FY2024: JELMYTO rev $90.4M; net loss $126.9M; guides FY2025 rev $94-98M
UGN-102 NDA under FDA review; PDUFA June 13, 2025; 18-month DOR 80.6% in Phase 3 ENVISION trial.
UroGen acquires ICVB-1042 assets from IconOVir for shares, milestone, and royalties
UroGen issued 374,843 ordinary shares (worth $4.0M) to IconOVir as upfront consideration.
UroGen Q3 revenue $25.2M, net loss $23.7M; UGN-102 PDUFA June 2025; cuts FY revenue view
JELMYTO Q3 net product revenue $25.2M (+21% YoY from $20.9M).
UroGen Pharma appoints Christopher Degnan as CFO; Don Kim resigns effectively Oct 8, 2024
Don Kim resigned as CFO, principal financial and accounting officer effective Oct 8, 2024; will provide part-time consulting through Apr 28, 2025 for $36,260.
UroGen Pharma submits NDA to FDA for UGN-102 for low-grade intermediate-risk NMIBC
Completed NDA submission for UGN-102 to the U.S. FDA.
UroGen ahead of schedule completing UGN-102 NDA; Q2 revenue $21.8M, net loss $33.4M
UGN-102 NDA completion imminent; potential FDA decision as early as Q1 2025 assuming priority review.
UroGen Pharma prices $107.5M public offering of 5M shares at $17.50, plus pre-funded warrants
Offering: 5,000,000 ordinary shares at $17.50/share plus 1,142,857 pre-funded warrants at $17.499 each.
UroGen reports positive DOR data from Phase 3 ENVISION trial for UGN-102 in bladder cancer
12-month DOR KM estimate for CR patients: 82.3% (95% CI: 75.9%-87.1%); predicted median DOR of 40 months.
UroGen Q1 net loss $32.3M; JELMYTO revenue up 10% to $18.8M; UGN-102 NDA on track
Net loss $32.3M ($0.97/share) vs $30.2M ($1.30) in Q1 2023; JELMYTO revenue $18.8M, +10% YoY.
UroGen Pharma FY2023: JELMYTO revenue $82.7M (+28% YoY), net loss narrows, UGN-102 NDA on track
Full year JELMYTO net revenue $82.7M, up ~28% YoY from $64.4M; Q4 revenue $23.5M (+30% YoY).
UroGen receives Teva Paragraph IV notice challenging two Jelmyto patents expiring 2031
Teva filed ANDA seeking FDA approval for a generic version of Jelmyto (mitomycin) for pyelocaliceal solution.
UroGen licenses medac's mitomycin formulation for RTGel combo; plans Phase 3 for UGN-103
Exclusive worldwide royalty-free license from medac for 80 mg mitomycin + 640 mg urea formulation combined with RTGel.
UroGen Q3 JELMYTO revenue $20.9M (+30% YoY); FDA agrees to rolling NDA for UGN-102
JELMYTO net product revenue $20.9M in Q3 2023, up ~30% from $16.1M in Q3 2022.
UroGen reports record Q2 JELMYTO revenue of $21.1M, positive Phase 3 data for UGN-102
Q2 2023 JELMYTO net revenue $21.1M (+27% YoY); net loss $24.1M ($1.03/share) vs $26.7M ($1.18) year ago.
UroGen raises $120M from institutions; UGN-102 Phase 3 trials meet endpoints
$120M gross proceeds from private placement at $9.54/share led by RA Capital and Great Point Partners.
UroGen Pharma Q1 2023 JELMYTO revenue $17.2M (+27% YoY); net loss $30.2M
JELMYTO net product revenue $17.2M, up ~27% from $13.6M in Q1 2022.
UroGen Pharma reports FY2022 JELMYTO revenue of $64.4M (+34% YoY); guides FY2023 revenue $76-86M
JELMYTO net revenue for FY2022: $64.4M, up 34% from $48.0M in FY2021; Q4 revenue: $18.1M.
UroGen Q3 JELMYTO revenue up 41% to $16.1M; net loss narrows to $25.8M
JELMYTO net product revenue $16.1M (+41% YoY); operating loss improved to $18.1M from $23.4M.
UroGen Q2 Jelmyto revenue $16.6M (+28% YoY); reaffirms FY22 guidance $70-80M
Q2 Jelmyto net revenue $16.6M, up 22% QoQ and 28% YoY from $13.0M.
UroGen shareholders reject say-on-pay and compensation policy; approve equity plan increase
Advisory vote on executive compensation failed: 5.7M against vs 4.2M for.
UroGen Q1 Jelmyto revenue $13.6M (+81% YoY); net loss $28.4M; cash $137.1M
Jelmyto net revenue $13.6M, +81% vs Q1 2021 ($7.5M).
UroGen Pharma CFO resigns; reports FY2021 Jelmyto revenue $48M, net loss $110.8M
CFO Molly Henderson resigns effective March 25, 2022; replaced by Dong Kim (VP Finance).
UroGen Pharma enters $100M term loan facility with BPCR Limited Partnership
Term loans up to $100M; Tranche A $75M at closing, Tranche B $25M optional by Dec 31, 2022.
UroGen Q3 Jelmyto rev $11.4M; ends Allergan pact; shifts UGN-102 trial to single-arm Phase 3
Q3 2021 net product revenue $11.4M; net loss $30.2M ($1.35/share) vs $28.8M loss ($1.31) in Q3 2020.
UroGen to start new Phase 3 study for UGN-102; stops ATLAS enrollment
New single-arm Phase 3 pivotal study for UGN-102 in low-grade intermediate-risk non-muscle invasive bladder cancer expected to start early 2022, enrolling ~220 patients at 90 sites.
pursuant to which Mr. Kim resigned from his positions as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, effective October 8, 2024
the Company appointed Christopher Degnan as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, effective on the Effective Date.
On September 12, 2024, Fred E. Cohen, M.D., D.Phil., notified UroGen Pharma Ltd. (the “Company”) of his resignation as a director of the Company, effective immediately.
appointed James A. Robinson Jr. to fill the vacancy on the Board and to hold office until the Company’s 2023 Annual Meeting of Shareholders
On November 8, 2022, Daniel G. Wildman was appointed to the board of directors (the “Board”) of UroGen Pharma Ltd., an Israeli company (the “Company”), to fill a vacancy on the Board and to hold office until the Company’s 2023 Annual Meeting of Shareholders
On September 8, 2022, Leana Wen, M.D., MSc was appointed to the board of directors (the “Board”) of UroGen Pharma Ltd., an Israeli company (the “Company”), to fill a vacancy on the Board and to hold office until the Company’s 2023 Annual Meeting of Shareholders and was also appointed to the Audit Committee of the Board.
Effective as of March 25, 2022 (the “Effective Date”), the Company appointed Dong (Don) Kim as Chief Financial Officer of the Company, as well as the Company’s principal financial officer and principal accounting officer, replacing Ms. Henderson in such capacities.
On March 17, 2022, Molly Henderson tendered her resignation as the Company’s Chief Financial Officer, effective March 25, 2022.
Max materiality 0.95 · Median 0.65 · Most common event earnings